NOTES TO THE FINANCIAL STATEMENTS
MARCH 31, 2016 AND MARCH 31, 2015
AUDITED
NOTE 1 - ORGANIZATION AND
BUSINESS OPERATIONS
Organization and Description of Business
ALTAIR INTERNATIONAL CORP. (the “Company”) was
incorporated under the laws of the State of Nevada on December 20, 2012. The Company is in the development stage as defined under
Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915-205 "Development-Stage
Entities.”
The Company has entered into a strategic alliance with Cure
Pharmaceutical Corporation (“CURE”), a California company engaged in the development of oral thin film (“OTF”)
for the delivery of nutraceutical, over-the-counter and prescription products. Currently this alliance is comprised of an Exclusive
License and Distribution Agreement for CURE’s Sildenafil (commonly known as Viagra) Products throughout Asia, Brazil, the
Middle East and Canada acquired at a cost of $200,000 while a Joint Venture Agreement for the procurement of converting and packaging
equipment specific for oral thin film products has been proposed through a Letter of Intent. In addition, Altair and Cure have
agreed to enter into further joint ventures or other business relationships for the purpose of completing the development and marketing
of additional products, and for license and distribution agreements for additional Cure products such as aspirin, sleep-aid, topical
muscle and joint pain relief, and electrolytes delivered through OTF or other methods. Altair has advanced $360,000 to CURE in
this regard.
The Company had previously planned to commence operations
in the architectural field and to be responsible for the concept architectural vision of future private and public buildings as
well as municipal organized public areas. This plan was abandoned in the 2015 fiscal year in favor of the business operations described
above.
Since inception (December 20, 2012) through March 31, 2016
the Company has not generated any revenue and has accumulated losses of $242,594.
NOTE
2 - GOING CONCERN
The financial statements
have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities
in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in
an accumulated deficit of $242,594 as of March 31, 2016 and further losses are anticipated in the development of its business raising
substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern
is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its
obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance
operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of common
stock.
NOTE 3 - SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
Basis of Presentation
The accompanying financial statements have been prepared
in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations
of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments,
which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company
as of and for the years ending March 31, 2016 and 2015.
Cash and Cash Equivalents
For purposes of the statement of cash flows, the Company
considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.
The Company's bank accounts are deposited in insured institutions.
The funds are insured up to $250,000. At March 31, 2016 the Company's bank deposits did not exceed the insured amounts.
Basic and Diluted Income (Loss) Per Share
The Company computes loss per share in accordance with “ASC-260”,
“Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement
of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average
number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares
outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.
Income Taxes
The Company follows the liability method of accounting for
income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences
attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences).
The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that
includes the enactment date.
Fair Value of Financial Instruments
FASB ASC 820 "Fair Value Measurements and Disclosures"
establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes
the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.
These tiers include:
Level 1: defined as observable inputs such as quoted prices
in active markets;
Level 2: defined as inputs other than quoted prices
in active markets that are either directly or indirectly observable; and
Level 3: defined as unobservable inputs in which little
or no market data exists, therefore requiring an entity to develop its own assumptions.
The carrying amounts of financial assets and liabilities,
such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.
Use of Estimates
The preparation of financial statements
in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements
and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those
estimates.
NOTE 4 – PROMISSORY NOTE
On March 6, 2015, the Company executed a convertible
promissory note for $100,000 with Williams Ten, LLC. The note was due in ninety days, has a $10,000 one-time interest payment due
at maturity and requires the issuance of 10,000 shares of common stock. Any unpaid principal and interest at the end of the term
is convertible into shares of common stock at 50% of the average closing price for the ten days prior to the end of the term of
the note. The fair value of the common stock issued was determined to be $9,091 based on its fair value relative to the fair value
of the debt issued. This amount has been recorded as a debt discount and was amortized utilizing the interest method of accretion
over the term of the note. In addition, due to the variable nature of the conversion feature which has no explicit limit on the
number of shares that could be required to be issued, the company bifurcated the conversion feature and accounted for it as a derivative
liability. The Company recorded the derivative liability at its fair value of $100,004 based on the Black Scholes Merton pricing
model and a corresponding debt discount of $90,909 and derivative expense charge of $9,095. As of March 31, 2016, $100,000 of the
debt discount has been amortized to interest expense and the Company fair valued the derivative at $100,000. This Note is currently
past due; however repayment terms are being renegotiated.
On May 26, 2015, the Company executed a Promissory Note
for $50,000 with Sareja Holdings, LLC. The note is due in thirty days, has a 10% per annum interest rate and requires the issuance
of 50,000 shares of common stock. The fair value of the 50,000 shares of common stock issued was determined to be $25,000 based
on its fair value relative to the fair value of the debt issued. This amount has been recorded as a debt discount and was amortized
utilizing the interest method of accretion over the term of the note. As of March 31, 2015, $25,000 of the debt discount has been
amortized to interest expense. On November 24, 2015, the company converted the $50,000 principle and $2,506 of accrued interest
into 50,000 shares of common stock satisfying the debt in full.
NOTE 5 – COMMON STOCK
The Company has 75,000,000 common shares authorized with
a par value of $0.001 per share.
During the period December 20, 2012 (inception) to March
31, 2013, the Company sold a total of 3,000,000 shares of common stock for total cash proceeds of $3,000. In November and December
2013, the Company sold a total of 1,235,000 shares of common stock for total cash proceeds of $24,700. During the period December
20, 2012 (inception) to March 31, 2014, the Company sold a total of 4,235,000 shares of common stock for total cash proceeds of
$27,700.
On February 9, 2015, the Company affected a seven for one
forward split of its common stock. As a result of this forward split, the Company had 29,645,000 common shares issued and outstanding
at March 31, 2015.
During the twelve month period ended March 31, 2016, the
Company sold a total of 302,000 common shares for total cash consideration of $265,006. The Company had 29.947,000 common shares
issued and outstanding at March 31, 2016.
NOTE 6 – RELATED PARTY TRANSACTIONS
Since inception through March 31, 2016 Directors have loaned
the Company $244,374 to pay for incorporation costs, general and administrative expenses and professional fees, the acquisition
of sales and distribution licenses and advances to Cure Pharmaceutical. As of March 31, 2016, total loan amount was $244,374
($353,425 on March 31, 2015). The loan is non-interest bearing, due upon demand and unsecured.
NOTE 7 – SUBSEQUENT EVENTS
The Promissory Note due to Williams Ten, LLC disclosed
in Note 4 was not repaid on June 6, 2015 as required by the terms of the Note and remains outstanding as of June 10, 2016.
In accordance with ASC 855-10, the Company has
analyzed its operations from March 31, 2016 to July 25, 2016 and has determined that it does not have any further material subsequent
events to disclose in these financial statements.